2022
Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryCreatinineHumansImmune Checkpoint InhibitorsKidneyNephritis, InterstitialConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activation
2020
Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study
Cortazar FB, Kibbelaar ZA, Glezerman IG, Abudayyeh A, Mamlouk O, Motwani SS, Murakami N, Herrmann SM, Manohar S, Shirali AC, Kitchlu A, Shirazian S, Assal A, Vijayan A, Renaghan AD, Ortiz-Melo DI, Rangarajan S, Malik AB, Hogan JJ, Dinh AR, Shin DS, Marrone KA, Mithani Z, Johnson DB, Hosseini A, Uprety D, Sharma S, Gupta S, Reynolds KL, Sise ME, Leaf DE. Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study. Journal Of The American Society Of Nephrology 2020, 31: 435-446. PMID: 31896554, PMCID: PMC7003302, DOI: 10.1681/asn.2019070676.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedB7-H1 AntigenFemaleHumansKidneyMaleMiddle AgedNephritis, InterstitialProgrammed Cell Death 1 ReceptorRetrospective StudiesRisk FactorsConceptsExtrarenal immune-related adverse eventsImmune-related adverse eventsMulticenter studyRenal prognosisKidney recoveryAdverse eventsMost patientsClinical featuresCombination immune checkpoint inhibitor therapyImmune checkpoint inhibitor initiationImmune checkpoint inhibitor rechallengeImmune checkpoint inhibitor therapyProton pump inhibitor useComplication of immunotherapyLower baseline eGFRNew dialysis requirementWorse renal prognosisCheckpoint inhibitor therapyImmune checkpoint inhibitorsCheckpoint inhibitor initiationBaseline eGFRSubnephrotic proteinuriaCheckpoint inhibitorsDialysis requirementControl patients
2016
Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients
Shirali AC, Perazella MA, Gettinger S. Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients. American Journal Of Kidney Diseases 2016, 68: 287-291. PMID: 27113507, DOI: 10.1053/j.ajkd.2016.02.057.Peer-Reviewed Original ResearchConceptsAcute interstitial nephritisPD-1 inhibitor therapyInhibitor therapyInterstitial nephritisLung cancerNon-small cell lung cancerAnti-PD-1 antibodyAcute kidney injuryImmune checkpoint inhibitorsT cell immunityCell lung cancerLung cancer patientsClinical trial dataRenal toleranceCheckpoint inhibitorsKidney injuryDeath-1Kidney biopsyCancer patientsPatientsTrial dataTherapyAdverse effectsDrugsNephritis